# Risperidone and nutritional intervention in neurodevelopmental disorders - URL: https://alisanburak.com/en/wcp-2026-posterler/ev0190 - Language: en - Last updated: not specified - Page title: Risperidone and nutritional intervention in neurodevelopmental disorders | WCP 2026 Summary > Risperidone may be beneficial for severe irritability and aggression, but prescribing it without metabolic monitoring and nutritional intervention constitutes… This page was translated automatically from Turkish. [Read the original](https://alisanburak.com/wcp-2026-posterler/ev0190) This page is an AI-assisted Turkish summary of the study presented at the 26th World Congress of Psychiatry. The study belongs to the presenting authors; please refer to the original source when citing it. EV0190 E-PosterPsychopharmacologyNarrative review # Risperidone and nutritional intervention in neurodevelopmental disorders RISPERIDONE AND NUTRITIONAL INTERVENTION IN NEURODEVELOPMENTAL DISORDERS Presenter: Florencia M. Sanabria Country: Argentina Institution: Instituto HELMAR Risperidone may be beneficial for severe irritability and aggression, but prescribing it without metabolic monitoring and nutritional intervention constitutes incomplete care. The study aims to reduce future risk while preserving clinical benefit by integrating metabolic monitoring and nutritional intervention in children and adolescents with neurodevelopmental disorders (NDDs) who are taking risperidone. The method is an updated narrative review of prescribing information, clinical trials, systematic reviews, and pediatric guidelines; the variables examined include behavioral efficacy, weight, body mass index z-score (BMI-z), waist circumference, blood pressure, lipids, glycemia and HbA1c, insulin, liver function, and eating behavior. The findings indicate that, in autism spectrum disorder (ASD) with severe irritability, the 8-week response rate is 69% with risperidone and 12% with placebo; in an 8-week clinical trial, weight gain was 2.7 kg with risperidone and 0.8 kg with placebo, with early increases in appetite and weight, and approximately one-third of patients reportedly gaining more than 7% of their body weight within 3 to 8 weeks (FDA data: an increase of more than 7% in approximately 33% of patients over 3 to 8 weeks). Prolonged use is associated with increases in weight and waist circumference, elevated triglycerides, LDL and total cholesterol, reduced HDL, and increased glycemia and insulin levels; risk is further increased by sedation, food selectivity, sleep problems, and low physical activity. The proposed metabolic monitoring pathway has four stages: at baseline, assessment of BMI-z, waist circumference, blood pressure, medical history, diet, and sleep, together with baseline laboratory tests; at weeks 4 to 8, assessment of appetite, somnolence, weight, adherence to the nutritional plan, and a warning threshold of 5% weight gain; at month 3, repeat measurements of weight, waist circumference, and blood pressure, with lipid and glycemia testing if risk factors or changes are present; at months 6 to 12, reassessment of the need for treatment, use of the lowest effective dose, and annual laboratory tests. Recommendations include initiating nutritional intervention from day one, family-based planning, reducing ultra-processed foods and sugary drinks, gradual changes tailored to sensory-based food selectivity, and physical activity and sleep goals; if weight gain persists, metformin may be considered under specialist supervision, but it does not replace lifestyle measures or monitoring. In conclusion, the review emphasizes that risperidone safety depends not only on behavioral response but also on effective monitoring, and that lipids, glycemia, and nutrition should be addressed alongside behavior. [View the original poster](https://cslide.ctimeetingtech.com/wcp26/attendee/eposter/file/1236) How to cite this study APA 7: Sanabria, F. M. (2026, September 23-26). Risperidone and nutritional intervention in neurodevelopmental disorders [E-poster]. 26th WPA World Congress of Psychiatry (WCP 2026), Stockholm, Sweden. https://cslide.ctimeetingtech.com/wcp26/attendee/eposter/file/1236 Vancouver: Sanabria FM. Risperidone and nutritional intervention in neurodevelopmental disorders [e-poster]. 26th WPA World Congress of Psychiatry (WCP 2026); 2026 Sep 23-26; Stockholm, Sweden. Available from: https://cslide.ctimeetingtech.com/wcp26/attendee/eposter/file/1236 Author names and title formatting were generated automatically from the congress system; please check them against the original poster before use. ## On the same topic - [Açığı kapatmak: erişkin DEHB ilacı başlanmadan önce EKG sevk uyumunun iyileştirilmesi, kapalı döngü klinik denetim](https://alisanburak.com/en/wcp-2026-posterler/ev0088) - [Anksiyete bozukluğu olan hastalarda psikobiyotik müdahalesi: ısıl işlem görmüş Lactobacillus paracasei PS23'ün etkilerini inceleyen çift kör randomize kontrollü çalışma](https://alisanburak.com/en/wcp-2026-posterler/ev0126) - [Otizm spektrum bozukluğunda bumetanidin tedavi edici potansiyeli: güncel kanıtlar ve gelecek yönelimleri](https://alisanburak.com/en/wcp-2026-posterler/ev0157) - [Verbaskozid ile otizm spektrum bozukluğu tedavisinin mekanizmaları: ağ farmakolojisi, moleküler yerleştirme ve moleküler dinamik temelli inceleme](https://alisanburak.com/en/wcp-2026-posterler/ev0172) - [Otizm spektrum bozukluğunun çekirdek belirtilerinin tedavisinde kannabidiol: sistematik derleme](https://alisanburak.com/en/wcp-2026-posterler/ev0186) [All WCP 2026 summaries](https://alisanburak.com/en/wcp-2026-posterler) --- Kaynak / Source: https://alisanburak.com/en/wcp-2026-posterler/ev0190 İletişim / Contact: Bağdat Caddesi, Veli Güneysu Apt. No:453 K:4 D:9, Suadiye / Kadıköy, İstanbul · +90 532 642 95 25 · info@alisanburak.com · https://alisanburak.com/bagdat-caddesi-psikoterapi-iletisim